相关实验视频

Updated: Jan 8, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

ARTIA-Cervix:用于宫癌的适应性辐射治疗的前性试验

Jyoti S Mayadev¹, Kevin V Albuquerque², Jeremy G Price³

¹University of California San Diego, Department of Radiation Medicine and Applied Sciences, La Jolla, CA, USA.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

|December 17, 2025

概括

宫癌的适应性放射治疗可以减少严重的胃肠道毒性. 在ARTIA-Cervix试验中,研究了这种益处,将患者报告的结果与历史数据进行比较.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
妇科瘤学妇科瘤学

背景情况:

对于宫癌的传统放射治疗,由于解剖学变异,涉及很大的边缘.
适应性放射治疗 (ART) 通过每天调整计划,可以降低利率和潜在的毒性.
ARTIA-Cervix旨在评估ART对局部晚期宫癌中胃肠道 (GI) 毒性的影响.

研究的目的:

调查局部晚期宫癌患者接受适应性放射治疗的急性等级≥3患者报告的GI毒性率.
为了将观察到的胃肠道毒性率与非适应性外部光束放射治疗的历史数据进行比较.

主要方法:

ARTIA-Cervix是一项前性的多中心单臂试验.
患者每天接受45Gy的盆腔外辐射疗法,适应每天的情况,对所涉及的淋巴结进行剂量升级.
治疗包括同时使用西斯普拉丁的化疗,然后进行支架疗法.

主要成果:

主要终点是第5周GI毒性等级≥3的比率,通过患者报告结果评估.
该研究旨在招募130名参与者.
积累完成的目标是2027年12月,结果将在2028年春季提交.

结论:

适应性放射治疗有望减少治疗边际,改善宫癌患者的治疗结果.
在这种患者群体中,ARTIA-Cervix将提供有关ART疗效和安全性的关键数据.
进一步的分析将确定ART是否与传统放射治疗相比显著降低了肠道毒性.

关键词:

适应性辐射疗法适应性辐射疗法宫癌宫癌是什么妇科妇科医生妇科辐射辐射辐射辐射辐射辐射辐射

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...